Pyxis Oncology Inc. (PYXS)
PYXS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:Revenues), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1782223/000119312526118532/0001193125-26-118532-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | PYXS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | 2021 |
| SEC CIK | 0001782223 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $13.9M |
| Net income | -$79.6M |
| Operating income | -$84.4M |
| Net margin | -574.5% |
| Operating margin | -609.2% |
| Revenue growth | -14.2% |
| Cash | $15.4M |
| Total assets | $91.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 12.2× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-05 |
| Cash and burn | $3.9M cash; operating cash flow -$17.7M a quarter. | Report 2026-09-30 |
| Shares outstanding | 119,607,855 (2026-11-04); 62,264,215 a year earlier; 44,323,046 three years earlier. | Cover page 2026-11-04 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 2 S-3/F-3 shelf filings; 3 424B5 takedowns, 3 at the market | Latest 2026-10-01 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | Ernst & Young LLP, Boston, Massachusetts, United States | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $107K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | Not filed | -$20.0M | -$16.3M | $3.9M | No debt tags | Needs four quarters | 10-Q 2026-11-05 |
| Q2 2026 2026-06-30 | Not filed | -$25.3M | -$18.2M | $18.9M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q1 2026 2026-03-31 | Not filed | -$23.3M | -$26.0M | $5.8M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2025 2025-12-31 | $11.0M | -$18.1M | -$10.4M | $15.4M | No debt tags | $13.9M | 10-K 2026-03-23 |
| Q3 2025 2025-09-30 | $0 | -$22.0M | -$13.3M | $8.9M | No debt tags | Needs four quarters | 10-Q 2025-11-03 |
| Q2 2025 2025-06-30 | $2.8M | -$18.4M | -$17.3M | $10.7M | No debt tags | Needs four quarters | 10-Q 2025-08-14 |
| Q1 2025 2025-03-31 | Not filed | -$21.2M | -$22.5M | $12.8M | No debt tags | Needs four quarters | 10-Q 2026-08-13 |
| Q4 2024 2024-12-31 | $0 | -$35.6M | -$19.3M | $19.5M | No debt tags | $16.1M | 10-K 2026-03-23 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2026-10-01 |
| Latest annual report | 10-K | 2026-03-23 |
| Latest quarterly / interim | 10-Q | 2026-11-05 |
| Latest current report | 8-K | 2026-11-13 |
| Latest proxy | DEF 14A | 2026-10-21 |
Source: SEC EDGAR submissions feed, 361 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.8% |
| 1 month | -14.6% |
| 3 months | -47.5% |
| Year to date | +37.4% |
| 1 year | -64.7% |
| From 52-week high | -70.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ORMP | Oramed Pharmaceuticals Inc. | $3.90 | +5.12% | $169.6M |
| ANTX | AN2 Therapeutics Inc. | $4.47 | -1.76% | $169.6M |
| PRQR | ProQR Therapeutics N.V. | $1.18 | -16.31% | $166.5M |
| ELDN | Eledon Pharmaceuticals Inc. | $1.97 | -6.86% | $166.4M |
| IFRX | InflaRx N.V. | $1.18 | +0.85% | $173.9M |
| KRRO | Korro Bio Inc. | $12.71 | -6.61% | $174.5M |
| WHWK | Whitehawk Therapeutics Inc. | $3.01 | -1.63% | $177.6M |
| ADCT | ADC Therapeutics SA Common Shares | $1.25 | -6.72% | $159.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier